Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jorge Brothers

Urology Lubbock, TX Medical Doctor

NPI 1841232923 CMS profile 1098997

418 N Utica Ave, Lubbock, TX 79416

Open in the dashboard

General payments

$12,844

477 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jorge Brothers of Lubbock, TX is reported in the CMS Open Payments database as having received $12,844 across 477 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,188 54
2024 General $1,931 70
2023 General $1,920 75
2022 General $1,701 87
2021 General $2,203 84
2020 General $763 29
2019 General $3,137 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jorge Brothers
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Jorge Brothers were reported at $1,188. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Jorge Brothers Urology median Middle half National median
2019 $3,137 $480 $147–$1,201 $163
2020 $763 $246 $87–$645 $114
2021 $2,203 $358 $111–$1,000 $132
2022 $1,701 $476 $143–$1,263 $149
2023 $1,920 $560 $168–$1,461 $160
2024 $1,931 $563 $170–$1,464 $164
2025 $1,188 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $3,436 49 payments
  2. Janssen Biotech, Inc. $1,716 89 payments
  3. Dendreon Pharmaceuticals LLC $1,623 47 payments
  4. Astellas Pharma US Inc $932 82 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $756 37 payments
  6. PROCEPT BioRobotics Corporation $401 9 payments
  7. AbbVie, Inc. $389 16 payments
  8. NeoTract Inc. $384 8 payments
  9. Ferring Pharmaceuticals Inc. $342 14 payments
  10. Sumitomo Pharma America, Inc. $319 27 payments
  11. Other $2,546 99 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,640 469 payments
  2. Travel and Lodging $1,075 5 payments
  3. Education $129 3 payments
Products named General payments · program years 2019–2025
  1. PROVENGE $1,623 47 payments
  2. ERLEADA $1,613 88 payments
  3. AMS $1,497 14 payments
  4. XTANDI $801 60 payments
  5. MYRBETRIQ $754 69 payments
  6. Nubeqa $737 36 payments
  7. GEMTESA $395 31 payments
  8. UROLIFT $384 8 payments
  9. AMS 700 $382 5 payments
  10. ADSTILADRIN $321 13 payments
  11. Other $5,141 170 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

2,185

Median for Urology: 1,053

Drug cost

$178,020

Median for Urology: $101,464

Branded share of claims

25.4%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 97 $92,934
Gemtesa Vibegron Brand 15 $13,877
Mirabegron Er Mirabegron Brand 22 $10,704
Estradiol Generic 135 $10,230
Tamsulosin Hcl Generic 571 $10,092
Finasteride Generic 463 $6,442
Testosterone Cypionate Generic 94 $5,258
Np Thyroid Thyroid,pork Brand 77 $4,742
Nitrofurantoin Nitrofurantoin Macrocrystal Brand 78 $4,537
Testosterone Generic 22 $4,025

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$673,558

Of which drugs: $468,500

Medicare patients

534

Average age 75

Services billed

12,978

114 women, 420 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Ischemic heart disease 42%
Diabetes 33%
Cancer 28%
Chronic kidney disease 25%
Atrial fibrillation 22%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 27 171 $22,193

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PROVENGE
  • Dendreon Pharmaceuticals LLC $549
$549 — —
ERLEADA
  • Janssen Biotech, Inc. $390
$390 — —
GEMTESA
  • Sumitomo Pharma America, Inc. $144
$144 15 —
JELMYTO
  • UROGEN PHARMA, INC. $74
$74 — —
ADSTILADRIN
  • Ferring Pharmaceuticals Inc. $64
$64 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

477 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record